Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Indirect protection from rotavirus vaccines: a systematic review70
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada68
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States59
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response58
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic50
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy49
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?49
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions47
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study44
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children44
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China43
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review43
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China37
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus36
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study36
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection36
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis35
Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008–202434
The important lessons lurking in the history of meningococcal epidemiology33
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era31
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays30
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis28
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom28
Microarray patches: scratching the surface of vaccine delivery27
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany27
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada26
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy26
Addressing RSV infection in older adults: implications for public health policy26
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above26
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis25
Vaccine hesitancy among 0–6-year-olds’ guardians in Chongqing: a cross-sectional survey revealing how immunization program managers’ robust comprehensive capacity for adverse events following immuniza25
Birth order and influenza vaccination: a comparative study of behaviors and intentions between first-time and second-time Chinese parents24
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond24
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment23
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative23
Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years23
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion22
Vaccines preventing neonatal sepsis: focus on Group B Streptococcus , Klebsiella pneumoniae and 22
Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America22
Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States22
Travelers’ preferences for tick-borne encephalitis vaccination21
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan21
Cost-effectiveness of cell-based influenza vaccine in France21
COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 202121
TAK-003: development of a tetravalent dengue vaccine21
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru21
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis21
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany21
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China20
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect20
Reply to: Letter to Editor “Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine”20
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia20
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination20
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China19
Adjuvant system AS01: from mode of action to effective vaccines19
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems19
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population19
Vaccines against mpox: MVA-BN and LC16m819
Anti-neuraminidase immunity in the combat against influenza18
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine18
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o18
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children18
Vaccination policies for dentists and other dental professionals in Europe: a systematic report18
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination18
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study17
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–201917
The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study17
Impact of rotavirus vaccination on diarrheal disease burden of children in South America17
The durability of vaccine-induced protection: an overview17
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease17
Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan17
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan17
Suspended cell lines for inactivated virus vaccine production17
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines17
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?16
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review16
Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges16
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States16
Estimating the time required to reach HPV vaccination targets across Europe15
Pneumococcal conjugate vaccines in older adults and immunocompromised individuals15
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review15
Public health impact and return on investment of the pediatric immunization program in Poland15
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks15
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs15
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome15
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses14
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine14
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis14
Next generation live-attenuated influenza vaccine platforms14
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study14
Making COVID-19 mRNA vaccines accessible: challenges resolved14
Expert review on global real-world vaccine effectiveness against SARS-CoV-214
Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review13
Correction13
Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage13
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era13
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice13
Vaccines against SARS-CoV-2 variants and future pandemics13
Have mRNA vaccines sentenced DNA vaccines to death?13
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza13
COVID-19 and vaccination: myths vs science13
Health behaviors are largely not predictive of adverse events following influenza vaccination13
Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023/24 season in Spain13
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis12
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients12
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older12
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations12
Emergence of mRNA vaccines in the management of cancer12
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella12
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution12
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines12
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions12
0.26727294921875